Global Coalition Renames Polycystic Ovary Syndrome (PCOS) to PMOS, Signaling Fundamental Shift in Disease Definition

For nearly a century, millions of women have been told their irregular periods, fatigue, and weight struggles were caused by cysts on their ovaries. The very name of the condition—Polycystic Ovary Syndrome (PCOS)—pointed directly at the reproductive system. But that label has always been a medical misnomer. The "cysts" are not actually cysts, and for many women, the ovaries are merely the victims of a systemic hormonal cascade, not the root cause.[4][5]

In May 2026, an unprecedented global coalition of 56 medical societies and patient advocacy groups formally corrected the record. Following a 14-year consensus process published in The Lancet, PCOS has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). The change, endorsed by major bodies including the Endocrine Society and the American Society for Reproductive Medicine, marks a fundamental shift in how the medical community understands and treats the disorder.[1][2][3]

The original term, coined in the 1930s, described the appearance of enlarged ovaries on an ultrasound. But those fluid-filled sacs are actually arrested follicles—eggs that failed to mature and release due to hormonal imbalances. By focusing entirely on the ovaries, the old name inadvertently reduced a complex, whole-body endocrine disorder to a localized fertility problem.[3][4]

The new "PMOS" acronym forces a wider clinical lens. "Polyendocrine" acknowledges that multiple hormone systems are misfiring, including insulin, androgens (male hormones), and neuroendocrine signals. "Metabolic" highlights the condition's invisible but severe drivers: insulin resistance, which affects a vast majority of patients and dramatically increases the risk of type 2 diabetes, fatty liver disease, and cardiovascular complications.[1][2]

This is not merely a rebranding exercise; words dictate clinical focus. Because the old name centered on ovarian cysts, women without visible follicles on an ultrasound were frequently dismissed, contributing to a staggering 70% delayed diagnosis rate. Patients were often handed birth control pills to regulate their cycles and told to return only when they wanted to get pregnant, leaving the underlying metabolic havoc completely unaddressed.[1][4]

By elevating the metabolic and endocrine components to the title of the disease, the global consensus aims to fundamentally change how doctors screen for it. A PMOS diagnosis should immediately trigger evaluations for blood sugar abnormalities, cholesterol levels, and cardiovascular risk, regardless of a patient's fertility goals. The shift validates the experiences of patients who have long argued their symptoms extended far beyond their reproductive organs.[2][5]

The transition will not happen overnight. Medical records, insurance billing codes, and clinical guidelines will carry the PCOS label for a transitional period of at least three years as the International Classification of Diseases updates its systems for 2028. Furthermore, researchers are still debating whether the diagnostic criteria themselves need to be updated to match the new name, as the current guidelines still heavily weigh reproductive symptoms.[1][4]

For the estimated 170 million women worldwide living with the condition, the immediate advice from endocrinologists is reassuring: your diagnosis remains valid, and no immediate medication changes are required. However, patients are encouraged to use the new PMOS framework to advocate for themselves. If your current care plan only addresses your menstrual cycle, it is time to ask your physician for a comprehensive metabolic screening.[2][4][5]